A Phase 1, Single-Center, Open-Label Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Intravenous Administration of SPR206 in Healthy Volunteers
Latest Information Update: 18 Mar 2024
At a glance
- Drugs SPR-206 (Primary)
- Indications Acinetobacter infections; Gram-negative infections
- Focus Pharmacokinetics
- Acronyms BAL
- Sponsors Spero Therapeutics
Most Recent Events
- 13 Mar 2024 According to a Spero Therapeutics media release, results from this study were published in Antimicrobials and Chemotherapy in July 2023.
- 19 Oct 2022 According to a Spero Therapeutics media release, data from this trial will be presented at the Infectious Disease Society of America (IDSA) IDWeek™ 2022.
- 16 Feb 2022 Topline results presented in a Spero Therapeutics media release.